Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.

Journal for Immunotherapy of Cancer
Chiara MassaBarbara Seliger

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer (BC). Due to the absence of targets such as HER2 or hormone receptors, early TNBC is treated with surgery and chemotherapy. Since TNBC is also considered the most immunogenic type of BC with tumor infiltrating lymphocytes that are predictive for chemotherapy response and prognostic for patients' survival, many different immunotherapeutic strategies are currently explored in clinical trials for the treatment of this disease. In order to efficiently combine chemotherapy with immunotherapy, it is important to evaluate the effect of chemotherapy on immune cells in vivo. Peripheral blood was taken from 56 patients with TNBC undergoing neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel (Nab-Pac) followed by epirubicin and cyclophosphamide (EC) at three different time points. Multicolor flow cytometry was used to characterize the immune cell composition and functional properties along neoadjuvant chemotherapy. Whereas the first phase of the neoadjuvant chemotherapy did not significantly alter the patients' immune cell composition, after the second phase of chemotherapeutic administration most B cells (>90%) were lost and the frequency of...Continue Reading

References

Sep 6, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Lei ZhangSidong Xiong
Mar 15, 2012·Current Medicinal Chemistry·M R ShurinG V Shurin
Nov 15, 2013·Science Translational Medicine·Christopher G KanakryLeo Luznik
Jan 9, 2014·Nature Communications·William VermiMarco A Cassatella
Jan 6, 2015·The Journal of Biological Chemistry·Anil K ChauhanRichard J DiPaolo
Mar 22, 2018·Technology in Cancer Research & Treatment·Mariel Garcia-ChagollanLuis Felipe Jave-Suárez
Aug 30, 2018·NPJ Breast Cancer·Kim R M BlenmanPeter P Lee
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Nov 11, 2018·Cancer Immunology, Immunotherapy : CII·Charlotte M HuijtsUNKNOWN Dutch WIN-O Consortium
Jan 4, 2019·Breast Cancer Research and Treatment·Dilan A PatelJian L Campian

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
blood draw
dissection

Software Mentioned

GeparNuevo
GraphPad Prism
SlanMo

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.